相似文献
1
Editorial: Balanced and Unbalanced Immune Response to Dengue Virus in Disease Protection and Pathogenesis.
Front Immunol. 2022 Feb 11;13:835731. doi: 10.3389/fimmu.2022.835731. eCollection 2022.
2
Editorial: Emerging Concepts in Dengue Pathogenesis and Host Innate Immune Response.
Front Cell Infect Microbiol. 2021 Jun 25;11:708484. doi: 10.3389/fcimb.2021.708484. eCollection 2021.
3
Immune Response to Dengue and Zika.
Annu Rev Immunol. 2018 Apr 26;36:279-308. doi: 10.1146/annurev-immunol-042617-053142. Epub 2018 Jan 18.
4
The battle between infection and host immune responses of dengue virus and its implication in dengue disease pathogenesis.
ScientificWorldJournal. 2013;2013:843469. doi: 10.1155/2013/843469. Epub 2013 Feb 10.
5
Innate Immune Cytokine Profiling and Biomarker Identification for Outcome in Dengue Patients.
Front Immunol. 2021 Jul 14;12:677874. doi: 10.3389/fimmu.2021.677874. eCollection 2021.
6
Recent advances in dengue pathogenesis and clinical management.
Vaccine. 2015 Dec 10;33(50):7061-8. doi: 10.1016/j.vaccine.2015.09.103. Epub 2015 Oct 14.
7
The Involvement of Neuroinflammation in Dengue Viral Disease: Importance of Innate and Adaptive Immunity.
Neuroimmunomodulation. 2019;26(3):111-118. doi: 10.1159/000501209. Epub 2019 Jul 26.
8
Nanoparticle delivery of a tetravalent E protein subunit vaccine induces balanced, type-specific neutralizing antibodies to each dengue virus serotype.
PLoS Negl Trop Dis. 2018 Sep 24;12(9):e0006793. doi: 10.1371/journal.pntd.0006793. eCollection 2018 Sep.
9
Adaptive Immunity to Dengue Virus: Slippery Slope or Solid Ground for Rational Vaccine Design?
Pathogens. 2020 Jun 15;9(6):470. doi: 10.3390/pathogens9060470.
10
Dengue virus and the host innate immune response.
Emerg Microbes Infect. 2018 Oct 10;7(1):167. doi: 10.1038/s41426-018-0168-0.
引用本文的文献
1
Host-Pathogen Interaction Interface: Promising Candidate Targets for Vaccine-Induced Protective and Memory Immune Responses.
Vaccines (Basel). 2025 Apr 16;13(4):418. doi: 10.3390/vaccines13040418.
本文引用的文献
1
Dengue mouse models for evaluating pathogenesis and countermeasures.
Curr Opin Virol. 2020 Aug;43:50-58. doi: 10.1016/j.coviro.2020.09.001. Epub 2020 Sep 17.
2
Rapid Induction and Maintenance of Virus-Specific CD8 T and CD4 T Cells Following Protective Vaccination Against Dengue Virus Challenge in Humans.
Front Immunol. 2020 Mar 24;11:479. doi: 10.3389/fimmu.2020.00479. eCollection 2020.
3
Adaptive immune responses to primary and secondary dengue virus infections.
Nat Rev Immunol. 2019 Apr;19(4):218-230. doi: 10.1038/s41577-019-0123-x.
4
Antibody-dependent enhancement of severe dengue disease in humans.
Science. 2017 Nov 17;358(6365):929-932. doi: 10.1126/science.aan6836. Epub 2017 Nov 2.
5
Dissecting the human serum antibody response to secondary dengue virus infections.
PLoS Negl Trop Dis. 2017 May 15;11(5):e0005554. doi: 10.1371/journal.pntd.0005554. eCollection 2017 May.
6
Human CD4 T Cell Responses to an Attenuated Tetravalent Dengue Vaccine Parallel Those Induced by Natural Infection in Magnitude, HLA Restriction, and Antigen Specificity.
J Virol. 2017 Feb 14;91(5). doi: 10.1128/JVI.02147-16. Print 2017 Mar 1.
7
The human CD8+ T cell responses induced by a live attenuated tetravalent dengue vaccine are directed against highly conserved epitopes.
J Virol. 2015 Jan;89(1):120-8. doi: 10.1128/JVI.02129-14. Epub 2014 Oct 15.
8
Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells.
Proc Natl Acad Sci U S A. 2013 May 28;110(22):E2046-53. doi: 10.1073/pnas.1305227110. Epub 2013 Apr 11.
9
Immunodominant T-cell responses to dengue virus NS3 are associated with DHF.
Proc Natl Acad Sci U S A. 2010 Sep 28;107(39):16922-7. doi: 10.1073/pnas.1010867107. Epub 2010 Sep 13.
10
Predominance of HLA-restricted cytotoxic T-lymphocyte responses to serotype-cross-reactive epitopes on nonstructural proteins following natural secondary dengue virus infection.
J Virol. 1998 May;72(5):3999-4004. doi: 10.1128/JVI.72.5.3999-4004.1998.
Zotero 插件